CLEC7A (Dectin-1) is a C-type lectin pattern recognition receptor that specifically binds β-1,3 and β-1,6-linked glucans from fungal and bacterial cell walls 12. Upon glucan binding, CLEC7A recruits the tyrosine kinase SYK via its ITAM motif, triggering downstream signaling through CARD9-dependent and -independent pathways that activate NF-κB and MAPK cascades, promoting pro-inflammatory cytokine and chemokine production 34. The receptor is predominantly expressed on myeloid cells including macrophages, dendritic cells, and monocytes, where it mediates phagocytosis of fungal pathogens and enhances T-cell activation 5. CLEC7A plays complex roles in disease pathogenesis. While essential for antifungal immunity, CLEC7A-mediated signaling paradoxically promotes pathological outcomes in several conditions: it drives pulmonary fibrosis through Raf1-dependent macrophage differentiation 4, contributes to myocardial ischemia-reperfusion injury via enhanced M1 polarization and neutrophil infiltration 6, and promotes colorectal tumorigenesis by suppressing IL-22 signaling through PGE2-mediated mechanisms in myeloid-derived suppressor cells 7. Conversely, CLEC7A blockade with laminarin antagonists or SYK inhibitors shows therapeutic promise in fibrotic and malignant diseases. Notably, systemic CLEC7A antibodies can enhance microglial responses in Alzheimer's disease models 3, indicating context-dependent therapeutic applications.